Anti-HIV activity of (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)- thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism

Journal of Medicinal Chemistry

Volumn 48, Issue 12, 2005, Pages 3949-3952

  Chu, Chung K ^a   Yadav, Vikas ^a   Chong, Youhoon H ^a   Schinazi, Raymond F ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 HYDROXYMETHYL 1,3 DIOXOLAN 4 YL)THYMINE; 1,3 DIOXOLANE DERIVATIVE; ABACAVIR; ANTIVIRUS AGENT; DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE KINASE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG BINDING; DRUG CONFORMATION; DRUG MECHANISM; DRUG RESISTANCE; MOLECULAR MECHANICS; MOLECULAR MODEL; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE;

ANTI-HIV AGENTS; BINDING SITES; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MODELS, MOLECULAR; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; STEREOISOMERISM;

EID: 20444367260     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050060l     Document Type: Article

References (22)

1. (a) Miller, V.; Ait-Khaled, M.; Stone, C.; Griffin, P.; Mesogiti, D.; Cutrell, A.; Harrigan, R.; Staszewski, S.; Katlama, C.; Pearce, G. and Tisdale, M. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000, 14, 163-71.
2. (b) Miller, M. D.; Margot, N. A.; Hertogs, K.; Larder, B. and Miller, V. Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acid 2001, 20, 1025-8.
3. (c) Zhang, D.; Caliendo, A. M.; Eron, J. J.; DeVore, K. M.; Kaplan, J. C.; Hirsch, M. S.; Daquila, R. T. Resistance to 2,3,-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1994, 38, 282-287.
4. (a) Winters, M. A.; Shafer, R. W.; Jellinger, R. A.; Mamtora, G.; Gingeras, T. and Merigan, T. C. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob. Agents Chemother. 1997, 41, 757-762.
5. (b) St. Clair, M.; Martin, J. L.; Tudor-Williams, G.; Bach, M. C.; Vavro, C. L.; King, D. M.; Kellam, P.; Kemp, S. D.; Larder, B. A. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253, 1557-1559.
6. (a) Boucher, C. A.; Cammack, N.; Schipper, P.; Schuurman, R.; Rouse, P.; Wainberg, M. A. and Cameron, J. M. High-level resistance to (-) enantiomeric 2,-deoxy-3,-thiacytidine in vitro is due to one amino acid substitution in the catsilytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1993, 37, 2231-2234.
7. Quinn, J. B.; Borroto-Esoda, K.; Hinkle, J.; Shaw, A.; Harris, J.; Rousseau, F. Overview of the genotypic findings form emtricitabine-treated HIV+ patients. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. 2003, H-908.
8. Miller, V.; Ait-Khaled, M.; Stone, C.; Griffin, P.; Mesogiti, D.; Cutrell, A.; Harrigan, R.; Staszewski, S.; Katlama, C.; Pearce, G.; Tisdale, M. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 2000, 14, 163-71.
9. Rusconi, S.; La Seta Catamancio, S.; Citterio, P.; Bulgheroni, E.; Kurtagic, S.; Galazzi, M.; Croce, F.; Moroni, M.; Galli, M. Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine. Antivir. Ther. 2001, 6, 41-6.
10. Shafer, R. W.; Iversen, A. K.; Winters, M. A.; Aguiniga, E.; Katzenstein, D. A. and Merigan, T. C. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. J. Infect. Dis. 1995, 172, 70-78.
11. Pillay, D.; Taylor, S.; Richman, D. D. Incidence and implication of resistance against approved antiviral drugs. Rev. Med. Virol. 2000, 10, 231-253.
12. Gu, Z.; Wainberg, M. A.; Nguyen-Ba, N.; L'Heureux, L.; De Muys, J. M.; Bowlin, T. L.; Rando, R. F. Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob. Agents Chemother. 1999, 43, 2376-2382.
13. Furman, P. A.; Jeffrey, J.; Keifer, L. L.; Feng, J. Y.; Anderson, J. S.; Borroto-Esoda, K.; Hill, E.; Copeland, W. C.; Chu, C. K.; Sommadossi, J. P.; Liberman, I.; Schinazi, R. F.; Painter, G. R. Mechanism of action of 1-β-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-β-D-dioxolaneguanosine. Antimicrob. Agents Chemother. 2001, 45, 158-165.
14. (a) Chu, C. K.; Ahn, S. K.; Kim, H. O.; Ahn, S. K.; Beach, J. W.; Alves, A. J.; Jeong, L. S.; Islam, Q.; Roey, P. V.; Schinazi, R. F.; Asymmetric synthesis of enantiomerically pure (-)-(1′R,4′R)-dioxolane-thymine and its anti-HIV activity. Tetrahedron Lett. 1991, 32, 3791-3794.
15. (b) Kim, H. O.; Ahn, S. K.; Alves, A. J.; Beach, J. W.; Jeong, L. S.; Choi, B. G.; Van Roey, P.; Schinazi, R. F.; Chu, C. K Asymmetric synthesis of 1,3-dioxolane pyrimidine nucleosides and their anti-HIV activity. J. Med. Chem. 1992, 35, 1987-1995.
16. Miller, M. D.; Lamy, P. D.; Fuller, M. D.; Mulato, A. S.; Margot, N. A.; Cihlar, T.; Cherrington, J. M. Human Immunodeficiency Virus Type 1 Reverse Transcriptase Expressing the K70E Mutation Exhibits a Decrease in Specific Activity and Processivity. Mol. Pharmacol. 1998, 54, 291-97.
17. Jeffery, J. L.; Feng, J. Y.; Qi, C. C. R.; Anderson, K. S.; Furman, P. A. Dioxolane Guanosine 5′-Triphosphate, an Alternative Substrate Inhibitor of Wild-type and Mutant HIV-1 Reverse Transcriptase: Steady State and Pre-Steady State Kinetic Analyses. J. Biol. Chem. 2003, 278, 18971-18979.
18. Arion, D.; Kaushik, N.; McCormick, S.; Borkow, G.; Parniak, M. A. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′- deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998, 37, 15908-15917.
19. Ueno, T.; Mitsuya, H. Comparative Enzymatic Study of HIV-1 Reverse Transcriptase Resistant to 2′,3′-Dideoxynucleotide Analogues Using the Single-Nucleotide Incorporation Assay. Biochemistry 1997, 36, 1092-1099.
20. Carroll, S. S.; Geib, J.; Olsen, D. B.; Stahlhut, M.; Shafer, J. A.; Kuo, L. C. Sensitivity of HIV-1 Reverse Transcriptase and Its Mutants to Inhibition by Azidothymidine Triphoaphate. Biochemistry 1994, 33, 2113-2120.
21. Ueno, T.; Shirasaka, T.; Mitsuya, H.; Enzymatic Characterization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Resistant to Multiple 2′,3′-Dideoxynucleoside 5′-Triphosphates. J. Biol. Chem. 1995, 270, 23605-23611.
22. Unpublished results.